United Therapeutics (NASDAQ:UTHR) Stock: Insider Christopher Patusky Sells 1,210 Shares

United Therapeutics Corporation (NASDAQ:UTHR) Director Christopher Patusky sold 1,210 shares of the business’s stock in a transaction dated Monday, November 9th. The stock was sold at an average price of $580.00, for a total transaction of $701,800.00. Following the sale, the director directly owned 2,140 shares of the company’s stock, valued at approximately $1,241,200. The trade was a 36.12% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website.

United Therapeutics Stock Up 1.2%

Shares of United Therapeutics stock opened at $595.66 on Thursday. The business has a 50 day moving average price of $538.56 and a 200-day moving average price of $535.20. United Therapeutics Corporation has a 52 week low of $452.44 and a 52 week high of $614.23. The company has a market cap of $25.37 billion, a PE ratio of 22.48, a price-to-earnings-growth ratio of 3.94 and a beta of 0.49.

United Therapeutics (NASDAQ:UTHR) last posted its quarterly earnings data on Wednesday, November 4th. The biotechnology company reported $5.71 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $6.01 by ($0.30). United Therapeutics had a return on equity of 19.18% and a net margin of 38.61%. The firm had revenue of $832.50 million for the quarter, compared to analysts’ expectations of $781.14 million. During the same period in the prior year, the firm earned $7.16 earnings per share. United Therapeutics’s revenue was up 4.1% compared to the same quarter last year. As a group, research analysts anticipate that United Therapeutics Corporation will post 24.90 EPS for the current year.

United Therapeutics declared that its Board of Directors has authorized a share buyback program on Thursday, October 22nd that authorizes the company to buy back $2 billion in shares. This repurchase authorization authorizes the biotechnology company to purchase up to 8.3% of its stock through open market purchases. Share repurchase programs are generally a sign that the company’s leadership believes its shares are undervalued.

Institutional Trading of United Therapeutics

Institutional investors and hedge funds have recently modified their holdings of the business. Toth Financial Advisory Corp grew its holdings in shares of United Therapeutics by 2,400.0% during the second quarter. Toth Financial Advisory Corp now owns 50 shares of the biotechnology company’s stock worth $27,000 after purchasing an additional 48 shares in the last quarter. Fiduciary Financial Advisors purchased a new stake in United Therapeutics in the second quarter valued at approximately $30,000. Gen Wealth Partners Inc purchased a new stake in United Therapeutics in the third quarter valued at approximately $34,000. Caitlin John LLC purchased a new stake in United Therapeutics in the second quarter valued at approximately $37,000. Finally, International Assets Investment Management LLC lifted its position in United Therapeutics by 426.7% during the first quarter. International Assets Investment Management LLC now owns 79 shares of the biotechnology company’s stock valued at $45,000 after purchasing an additional 64 shares during the last quarter. Hedge funds and other institutional investors own 94.08% of the company’s stock.

Analyst Upgrades and Downgrades

A number of research analysts have recently weighed in on UTHR shares. Raymond James Financial set a $720.00 target price on shares of United Therapeutics in a research report on Wednesday, November 4th. Jefferies Financial Group restated a “buy” rating and issued a $728.00 price objective on shares of United Therapeutics in a research report on Wednesday, October 14th. JPMorgan Chase & Co. lowered their target price on shares of United Therapeutics from $710.00 to $695.00 and set an “overweight” rating on the stock in a research note on Wednesday, October 28th. Royal Bank Of Canada raised their price target on shares of United Therapeutics from $697.00 to $725.00 and gave the company an “outperform” rating in a report on Thursday, November 5th. Finally, Leerink Partners boosted their price target on shares of United Therapeutics from $685.00 to $725.00 and gave the company an “outperform” rating in a research report on Monday, October 19th. Twelve equities research analysts have rated the stock with a Buy rating, three have given a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, United Therapeutics has a consensus rating of “Moderate Buy” and an average target price of $676.40.

United Therapeutics News Roundup

Investors following UTHR have been watching these news items:

• Positive Sentiment: HC Wainwright initiated coverage with a Buy rating and a $660 price target, above the share price cited in the background. Its forecasts call for EPS to rise from $27.46 in FY2026 to $53.67 in FY2030, signaling confidence in longer-term earnings growth. HC Wainwright coverage report
• Negative Sentiment: CEO Martine Rothblatt sold 9,500 shares on November 6 and another 9,500 shares across transactions on November 9. Director Christopher Patusky also sold 1,210 shares, reducing his position by 36.12%. Insider selling can weigh on sentiment, although both executives retain shares. SEC filing

United Therapeutics Company Profile

United Therapeutics is a biotechnology company that develops and commercializes treatments for serious diseases, with a primary focus on pulmonary arterial hypertension (PAH). Its therapies include treprostinil products delivered by injection, inhalation, or oral tablet, marketed under brands including Remodulin, Tyvaso, and Orenitram. The company also markets Unituxin, a treatment for high-risk neuroblastoma. Founded in 1996 by Martine Rothblatt, United Therapeutics is also pursuing technologies intended to address the shortage of transplantable organs.